The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant

European Journal of Pharmacology

Volumn 636, Issue 1-3, 2010, Pages 88-95

  Hansen, Henrik H ^a   Hansen, Gitte ^b,c   Tang Christensen, Mads ^b,c   Larsen, Philip J ^b,d   Axel, Anne Marie D ^a   Raben, Anne ^a   Mikkelsen, Jens D ^a,e  

^a NEUROSEARCH A S   (Denmark)

^b Rheoscience A/S   (Denmark)

^c Gubra   (Denmark)

^d ELI LILLY AND COMPANY   (United States)

^e Copenhagen University Hospital ^*  (Denmark)

Author keywords

Appetite suppression; Food intake; Insulin sensitivity; Monoamine reuptake inhibitor; Obesity; Weight loss

Indexed keywords

INSULIN; RIMONABANT; SIBUTRAMINE; TESOFENSINE;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENERGY EXPENDITURE; FOOD INTAKE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; LONG TERM CARE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SUBCUTANEOUS FAT; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; APPETITE; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOGENIC MONOAMINES; BLOOD GLUCOSE; CYCLOBUTANES; DIET; EATING; GLUCOSE TOLERANCE TEST; LIPIDS; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; OBESITY; PIPERIDINES; PYRAZOLES; RATS; TIME FACTORS; WEIGHT LOSS;

EID: 77952672353     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.026     Document Type: Article

References (36)

1. Astrup A., Madsbad S., Breum L., Jensen T.J., Kroustrup J.P., Larsen T.M. Effect of tesofensine on body weight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1906-1913.
2. Astrup A., Meier D.H., Mikkelsen B.O., Villumsen J.S., Larsen T.M. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring Md) 2008, 16:1363-1369.
3. Balcioglu A., Wurtman R.J. Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology 2000, 39:2352-2359.
4. Billes S.K., Cowley M.A. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 2007, 32:822-834.
5. Billes S.K., Cowley M.A. Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 2008, 33:1287-1297.
6. Bray G.A., Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 2007, 132:2239-2252.
7. Brown M., Bing C., King P., Pickavance L., Heal D., Wilding J. Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br. J. Pharmacol. 2001, 132:1898-1904.
8. Bush E.N., Shapiro R., Brune M.E., Knourek-Segel V.E., Droz B.A., Fey T., Lin E., Jacobson P.B. Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine 2006, 29:375-381.
9. Connoley I.P., Liu Y.L., Frost I., Reckless I.P., Heal D.J., Stock M.J. Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. 1999, 126:1487-1495.
10. Fernstrom J.D., Choi S. The development of tolerance to drugs that suppress food intake. Pharmacol. Ther. 2008, 117:105-122.
11. Fisas A., Codony X., Romero G., Dordal A., Giraldo J., Merce R., Holenz J., Vrang N., Sorensen R.V., Heal D., Buschmann H., Pauwels P.J. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br. J. Pharmacol. 2006, 148:973-983.
12. Fulton S., Pissios P., Manchon R.P., Stiles L., Frank L., Pothos E.N., Maratos-Flier E., Flier J.S. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 2006, 51:811-822.
13. Gary-Bobo M., Elachouri G., Gallas J.F., Janiak P., Marini P., Ravinet-Trillou C., Chabbert M., Cruccioli N., Pfersdorff C., Roque C., Arnone M., Croci T., Soubrie P., Oury-Donat F., Maffrand J.P., Scatton B., Lacheretz F., Le F.G., Herbert J.M., Bensaid M. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007, 46:122-129.
14. Geiger B.M., Behr G.G., Frank L.E., Caldera-Siu A.D., Beinfeld M.C., Kokkotou E.G., Pothos E.N. Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB J. 2008, 22:2740-2746.
15. Glick S.D., Haskew R.E., Maisonneuve I.M., Carlson J.N., Jerussi T.P. Enantioselective behavioral effects of sibutramine metabolites. Eur. J. Pharmacol. 2000, 397:93-102.
16. Goldstein D.J. Beneficial health effects of modest weight loss. Int. J. Obes. Relat. Metab. Disord. 1992, 16:397-415.
17. Golozoubova V., Strauss F., Malmlof K. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure. Pharmacol. Biochem. Behav. 2006, 83:517-527.
18. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
19. Heal D.J., Cheetham S.C., Prow M.R., Martin K.F., Buckett W.R. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br. J. Pharmacol. 1998, 125:301-308.
20. Heal D.J., Jagger E., Antel N., Finer D., Heal D., Krause G. Development, Regulatory and Marketing Challenges for Novel Anti-obesity Therapies. Obesity and Metabolic Disorders 2005, 73-91. IOS Press, Amsterdam, Netherlands.
21. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br. J. Pharmacol. 1997, 121:1613-1618.
22. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br. J. Pharmacol. 1997, 121:1758-1762.
23. Kahn B.B., Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 2000, 106:473-481.
24. Lehr T., Staab A., Tillmann C., Nielsen E.O., Trommeshauser D., Schaefer H.G., Kloft C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br. J. Pharmacol. 2008, 153:164-174.
25. Levin B.E., Dunn-Meynell A.A. Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R2222-R2228.
26. Meguid M.M., Fetissov S.O., Varma M., Sato T., Zhang L., Laviano A., Rossi-Fanelli F. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition (Burbank, Los Angeles County, Calif) 2000, 16:843-857.
27. Nelson D.L., Gehlert D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006, 29:49-60.
28. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschop J., Caldwell C., Woods S.C., Wittmann G., Watanabe M., Liposits Z., Fekete C., Reizes O., Rohner-Jeanrenaud F., Tschop M.H. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008, 57:2977-2991.
29. Palmiter R.D. Is dopamine a physiologically relevant mediator of feeding behavior?. Trends Neurosci. 2007, 30:375-381.
30. Paulsen S.J., Jelsing J., Madsen A.N., Hansen G., Lykkegaard K., Larsen L.K., Larsen P.J., Levin B.E., Vrang N. Characterization of beta-Cell Mass and Insulin Resistance in Diet-induced Obese and Diet-resistant Rats. Obesity (Silver Spring, Md.) 2010, 18:266-273.
31. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
32. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol. Biochem. Behav. 2006, 84:353-359.
33. Tizzano J.P., Stribling D.S., Perez-Tilve D., Strack A., Frassetto A., Chen R.Z., Fong T.M., Shearman L., Krieter P.A., Tschop M.H., Skolnick P., Basile A.S. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J. Pharmacol. Exp. Ther. 2008, 324:1111-1126.
34. Volkow N.D., Wise R.A. How can drug addiction help us understand obesity?. Nat. Neurosci. 2005, 8:555-560.
35. Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., Hesson L.A., Osei S.Y., Kaplan R., Stunkard A.J. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005, 353:2111-2120.
36. Wortley K.E., Heal D.J., Stanford S.C. Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors. Br. J. Pharmacol. 1999, 128:659-666.